Literature DB >> 21925042

Generic drug prescriptions following hospital discharge: a prospective study in France.

C Chu1, E Rudant, M Bonvalet, H Agostini, P Cavalié, L Bonhomme-Faivre, J Frenkiel, J Taillandier, A Boissonnas, D Vittecoq, B Wyplosz.   

Abstract

AIMS: Systematic generic prescription at discharge could reduce confusion on drug-name usage, decrease commercial influence on medicine, and reduce drug-related expenditures. This study aimed to analyze generic drug prescriptions at discharge from hospital and to estimate the potential savings associated with a total substitution policy (substitution of every substitutable drug for its cheapest generic counterpart).
METHODS: Drug prescriptions before admission and at discharge of all patients from three medical units of a university hospital were prospectively collected for five weeks without informing prescribers.
RESULTS: Prescriptions from 85 patients were analyzed. On admission, 68 patients (80%) received 413 drugs; 141 were substitutable brand-name drugs and 23 (16%), which were directly prescribed as generics. At discharge, 488 drugs were prescribed to the 85 patients; 180 were substitutable drugs but only 5 (2.8%) were written as generics on prescription pads, a decrease of 78% (p<0.0001) compared to admission. In average, generics were 18% less expensive than brand-name drugs. Some common therapeutic classes offered even greater price difference, such as proton-pump inhibitors (42%), statins (32%), or antihypertensive agents (28%). Potential savings from a total substitution policy at discharge were estimated to €1512 per 1000 patients per week; for lifetime drugs, savings amounted to €18,960 per 1000 patients per year.
CONCLUSIONS: Very few drugs are written as generics on medical forms at discharge in France. Hospital practitioners should be encouraged to prescribe generics, particularly in chronic diseases. A broad generic prescription policy at hospital discharge would result in substantial savings for health insurance.
Copyright © 2011 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21925042     DOI: 10.1016/j.ejim.2011.01.016

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  2 in total

Review 1.  The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?

Authors:  Ameet Sarpatwari; Aaron S Kesselheim
Journal:  PLoS Med       Date:  2016-02-09       Impact factor: 11.069

2.  A price and use comparison of generic versus originator cardiovascular medicines: a hospital study in Chongqing, China.

Authors:  Wenjie Zeng
Journal:  BMC Health Serv Res       Date:  2013-10-05       Impact factor: 2.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.